Clinical trials: Psoriasis Patients
Psoriasis, Atopic Dermatitis
Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional Chinese Medicine
This study is a cross-sectional, observational investigation designed to develop and validate a noninvasive ocular imaging-based predictive model for major inflammatory skin diseases, including psoriasis, atopic dermatitis, and…
- Trial name
- NCT07434076
- Testing
- Questionnaire collection
- Volunteers
- 950 people, healthy volunteers welcome
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Genital Psoriasis, Scalp Psoriasis
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques.
- Trial name
- UnlIMMited (NCT05969223)
- Testing
- Risankizumab
- Where
- 38 sites in United States
- Volunteers
- 214 people
- Sponsor
- AbbVie
Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP)
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions.
- Conditions
- Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized Exanthematous Pustulosis
- Trial name
- LegitHealth BI (NCT07428915)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- AI Labs Group S.L
Skin Lesions, Melanocytic Nevi
Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.
This study aims to determine if an artificial intelligence (AI) medical device can help primary care doctors more accurately identify and manage various skin conditions.
- Conditions
- Skin Lesions, Melanocytic Nevi, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin
- Trial name
- LegitHealth PH (NCT07428941)
- Testing
- AI-based medical device for aided diagnosis in dermatological conditions
- Where
- Spain
- Volunteers
- 9 people
- Sponsor
- AI Labs Group S.L
Dermatitis, Melanoma (Skin Cancer)
Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
This study aims to determine if an artificial intelligence (AI) medical device can help doctors more accurately identify a wide variety of skin conditions and improve the efficiency of patient consultations.
- Conditions
- Dermatitis, Melanoma (Skin Cancer), Alopecia, Urticaria
- Trial name
- LegitHealthSAN (NCT07428954)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- AI Labs Group S.L
Psoriasis
Real-Life Evaluation of Guselkumab Dosing Interval Adjustments
"Guselkumab (Tremfya®) is a fully human monoclonal antibody that selectively targets interleukin-23 (IL-23), a key cytokine involved in the inflammatory pathways of psoriasis.
- Trial name
- NCT07430319
- Testing
- Guselkumab (Tremfya®)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Plaque Psoriasis
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P55 with Cosentyx in patients with moderate to severe plaque psoriasis
- Trial name
- NCT06630559
- Testing
- CT-P55, EU-approved Cosentyx
- Where
- Poland
- Volunteers
- 153 people
- Sponsor
- Celltrion
Psoriasis (PsO), PsA (Psoriatic Arthritis)
Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
The goal of this research study is to better understand if there is an association between non-alcoholic fatty liver disease (NAFLD) and active psoriatic disease (PD), and to assess the effect of Guselkumab (a medication approved…
- Conditions
- Psoriasis (PsO), PsA (Psoriatic Arthritis), NAFLD (Nonalcoholic Fatty Liver Disease)
- Trial name
- EMERGE (NCT07255781)
- Testing
- Guselkumab Prefilled Syringe [Tremfya]
- Sponsor
- University of California, San Diego
Psoriasis Vulgaris, Topical Administration
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
The goal of this clinical trial is to learn if a botanical Total Coumarin topical cream (TC Cream) works to treat psoriasis in adults. It will also learn about the safety of the topical TC Cream.
- Conditions
- Psoriasis Vulgaris, Topical Administration, Phase III
- Trial name
- PLANTCOAT-III (NCT07426120)
- Testing
- Total coumarin (TC) cream, Vehicle cream
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Psoriasis Research Institute of Guangzhou
Psoriasis
A Registry of Patients With Moderate to Severe Plaque Psoriasis
The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.
- Trial name
- PURE (NCT02786186)
- Testing
- Secikinumab
- Where
- 13 sites in Canada
- Volunteers
- 2,376 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis, Vitamin D3
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis.
- Trial name
- NCT04036188
- Testing
- Triamcinolone, Vitamin D3
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wright State University
Psoriatic Arthritis, Psoriasis
Psoriatic Arthritis and Psoriasis Treatment Decision Aid
The purpose of this study is to create and test a patient decision aid that facilitates the shared decision-making process when patients with psoriasis and/or psoriatic arthritis are starting or switching to a new therapy.
- Trial name
- DA (NCT03737045)
- Testing
- Decision Aid
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Pennsylvania
Psoriasis, Plaque Psoriasis
Role of Insulin Action in Psoriasis Pathogenesis
The goal of this study is to collect more information from people with plaque psoriasis and to determine if insulin plays a role in the pathogenesis of psoriasis.
- Conditions
- Psoriasis, Plaque Psoriasis, Insulin Resistance, PreDiabetes
- Trial name
- NCT06242847
- Testing
- Oral glucose tolerance test (OGTT), Skin punch biopsy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Plaque Psoriasis
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
- Trial name
- FRONTIER 1 (NCT05223868)
- Testing
- JNJ-77242113
- Where
- 76 sites in United States, Canada and 8 more
- Volunteers
- 255 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis (PsO), Obesity & Overweight
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid/calcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight/obesity and/or type…
- Conditions
- Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2
- Trial name
- SEMAPSO (NCT07401992)
- Testing
- Semaglutide (Rybelsus®)
- Where
- Mexico
- Volunteers
- 62 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Palmoplantar Pustulosis
A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan
The purpose of this study is to describe the treatment patterns of participants receiving systemic treatment for of palmoplantar pustulosis (PPP) in Japan.
- Trial name
- ProPuP (NCT04459507)
- Testing
- No intervention
- Where
- 39 sites in Japan
- Volunteers
- 276 people
- Sponsor
- Janssen Pharmaceutical K.K.
Plaque Psoriasis Patients
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
- Trial name
- NCT06842199
- Testing
- ICP-488 Tablets
- Where
- 46 sites in China
- Volunteers
- 383 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Vitiligo Vulgaris, Psoriasis
PALLAS Laser for Skin Diseases
The primary objective of this study is to get clinical experiences with the PALLAS laser in the treatment of skin conditions that respond well to UV light (vitiligo, psoriasis, alopecia areata, atopic dermatitis).
- Conditions
- Vitiligo Vulgaris, Psoriasis, Alopecia Areata, Atopic Dermatitis
- Trial name
- PALLAS-UV (NCT07250997)
- Testing
- UVB laser treatment
- Where
- Hungary
- Volunteers
- 50 people
- Sponsor
- Szeged University
Healthy, Plaque Psoriasis
A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.
This is a first-in-human, randomized, double- blind, placebo-controlled, dose escalation study to investigate how different doses of CAN10 are tolerated, taken up by the body and how long CAN10 stays in the body.
- Trial name
- NCT06143371
- Testing
- CAN10
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Moderate Plaque Psoriasis, Moderate Psoriasis
Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece
Psoriasis is a skin disorder wherein skin cells multiply faster than normal, making the skin itchy and look patchy and red. It is caused by an overactive immune system where the body attacks healthy tissue by mistake.
- Conditions
- Moderate Plaque Psoriasis, Moderate Psoriasis, Psoriasis
- Trial name
- REDEFINE (NCT06247319)
- Where
- 22 sites in Greece
- Volunteers
- 250 people
- Sponsor
- AbbVie